InVivo Therapeutics Holding (OTCBB:NVIV) Still Weighed Downward
InVivo Therapeutics Holding (OTCBB:NVIV) is going through a sensitive period, correcting a very strong climbing trend. Friday marked the ticker’s first day of net buying after three days of selling. A bit more than 200,000 stocks were bought up, and NVIV stood at $3.79 after dropping from its heights for a while. 
The drop in NVIV started after an 8-K filing mentioning in detail the personal investment schedule of CEO and CFO Frank M. Reynolds. He holds upward of 13 million company shares, and has the right to sell no more than 12,000 shares each trading day. While there is no current active promotion, this divestment schedule will certainly benefit from a boost in the NVIV price. The personality of Mr. Reynolds is also an important boost to the company, as he is shortlisted for a CFO of the Year Award from the Boston Business Journal.
Otherwise, NVIV relies on proof of the efficiency of treating spinal trauma patients. The company is equipped for the task with the following financials:
- $10.3 million cash
- $13.8 million total assets
- $28.17 million total liabilities
- $24.5 million derivative warrant debt
- No revenues so far
- $13.3 million quarterly loss until March 2013
The company is well-padded financially, although its task is also ambitious, the research is in quite an early stage and it would be a long time before any real results materialize. But even vaguely optimistic news tend to lift biotech stocks, so NVIV can always rely on short-term boosts.
NVIV is following the logic of biopharmaceutical companies as it develops its innovative spinal injury technologies. The hopes of a new treatment are the most powerful engine behind a stock’s climb. This was the case of AP Pharma, Inc. (OTCBB:APPA), which dropped suddenly after losing approval on one of its proposed treatments. Needless to say, negative news affected Titan Pharmaceuticals, Inc. (OTCBB:TTNP) even worse.
For NVIV, the new trading session will show if the company picks up again or goes in for a longer correction. NVIV did not manage to break through $5 and marked the 2013 peak at $4.75. Given the high levels reached relatively quickly, it is best to stay away from NVIV unless you can afford a longer correction.
